ARK Genomic Revolution ETF
ARKG
238 hedge funds and large institutions have $575M invested in ARK Genomic Revolution ETF in 2024 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 38 increasing their positions, 88 reducing their positions, and 40 closing their positions.
28% more call options, than puts
Call options by funds: $90.4M | Put options by funds: $70.7M
20% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 40
0% more funds holding
Funds holding: 238 → 238 (0)
2.8% less ownership
Funds ownership: 54.83% → 52.03% (-2.8%)
18% less capital invested
Capital invested by funds: $699M → $575M (-$125M)
57% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 88
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$51M |
| 2 |
Goldman Sachs
New York
|
+$44.7M |
| 3 |
Two Sigma Investments
New York
|
+$20.4M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.2M |
| 5 |
Jane Street
New York
|
+$2.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MMEA
Main Management ETF Advisors
San Francisco,
California
|
-$62.2M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$42.9M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$23.2M |
| 4 |
MM
Main Management
San Francisco,
California
|
-$16M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$10.1M |
ARKG Hedge Fund Activity: Q4 2024 in Review
238 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q4 2024, worth a combined $575M — down 18% from $699M a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new ARKG positions and 40 closed out — a net gain of 8 holders — while 38 added to existing stakes and 88 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $51M. The largest seller was Main Management ETF Advisors, exiting entirely with an estimated $62.2M sold.
- 238 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $575M of ARK Genomic Revolution ETF stock for Q4 2024, down 18% quarter-over-quarter.
- 48 funds opened new ARK Genomic Revolution ETF positions in Q4 2024 and 40 closed out, a net change of +8 holders.
- The largest ARK Genomic Revolution ETF buyer in Q4 2024 was Morgan Stanley, an estimated $51M added.
- The largest ARK Genomic Revolution ETF seller in Q4 2024 was Main Management ETF Advisors, an estimated $62.2M sold.
Based on aggregated 13F filings for Q4 2024.